ClinicalTrials.gg
RecruitingNCT07860372ImmunonutritioUpdated Oct 6, 2026

Immunonutrition vs EPA-DHA Enriched Nutritional Support in Patients With Cancer Undergoing Surgery

An observational study in Nutrition Aspect of Cancer, sponsored by Maimónides Biomedical Research Institute of Córdoba. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Maimónides Biomedical Research Institute of Córdoba · Observational

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 85 Years
Sex
All
01

Study summary

To compare clinical and molecular effects of nutritional support (immunonutrition or EPA-DHA enriched oral nutritional supplements) in patients with cancer undergoing surgery.

02

Conditions studied

  • Nutrition Aspect of Cancer

Browse trials for

Keywords

  • cancer
  • surgery
  • nutritional support
  • immunonutrition
  • EPA-DHA
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 80 is below the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Maimónides Biomedical Research Institute of Córdoba is the lead sponsor of 79 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with cancer undergoing surgery (primary tumor location; gastrointestinal tract, ovarian, peritoneal carcinomatosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with cancer undergoing surgery (primary tumor location; gastrointestinal tract, ovarian, peritoneal carcinomatosis)

Exclusion criteria

Exclusion Criteria:

  • End-stage liver disease
  • End-stage kidney disease
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with cancer undergoing surgery (primary tumor location: gastrointestinal tract, ovary)

    Patients undergo nutritional prehabilitation before surgery

    Dietary Supplement: Immunonutrition · Dietary Supplement: EPA-DHA

Interventions

  • Dietary supplementImmunonutrition

    Patients will receive nutritional advice and 2 oral nutritional supplements with arginine, fatty acids and nucleotides

  • Dietary supplementEPA-DHA

    Patients will receive nutritional advice and 2 oral nutritional supplements enriched with EPA and DHA

06

What researchers measure

Primary outcomes

  1. Body composition changes

    changes in fat mass, fat-free mass, lean mass and phase angle

    Time frame: 1-3 months

Secondary outcomes

  1. Cytokines changes

    Changes in circulating cytokines (IL6, IL8, MIP10)

    Time frame: 1-3 months

  2. Metabolites changes

    Changes in circulating metabolites including lipids and muscle-related metabolites

    Time frame: 1-3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 12 months is below that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartEst.
Nov 2, 2026
Primary completionEst.
Nov 2, 2027
CompletionEst.
Nov 2, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860372
Lead sponsor
Maimónides Biomedical Research Institute of Córdoba
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Nov 2, 2026 (estimated)
Primary completion
Nov 2, 2027 (estimated)
Completion
Nov 2, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Jose Carlos Garrido, PhD
Contact
josecarlos.garrido@imibic.org
957 736 571

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion